218 related articles for article (PubMed ID: 35477176)
1. Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests.
Owens L; Gulati R; Etzioni R
Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1298-1304. PubMed ID: 35477176
[TBL] [Abstract][Full Text] [Related]
2. Projecting the Impact of Multi-Cancer Early Detection on Late-Stage Incidence Using Multi-State Disease Modeling.
Lange JM; Gogebakan KC; Gulati R; Etzioni R
Cancer Epidemiol Biomarkers Prev; 2024 Jun; 33(6):830-837. PubMed ID: 38506751
[TBL] [Abstract][Full Text] [Related]
3. The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA.
Tafazzoli A; Ramsey SD; Shaul A; Chavan A; Ye W; Kansal AR; Ofman J; Fendrick AM
Pharmacoeconomics; 2022 Nov; 40(11):1107-1117. PubMed ID: 36038710
[TBL] [Abstract][Full Text] [Related]
4. Clinical performance and utility: A microsimulation model to inform the design of screening trials for a multi-cancer early detection test.
Dai JY; Zhang J; Braun JV; Simon N; Hubbell E; Zhang N
J Med Screen; 2024 Feb; ():9691413241228041. PubMed ID: 38304990
[TBL] [Abstract][Full Text] [Related]
5. Impact of screening participation on modelled mortality benefits of a multi-cancer early detection test by socioeconomic group in England.
Smittenaar R; Quaife SL; von Wagner C; Higgins T; Hubbell E; Lee L
J Epidemiol Community Health; 2024 May; 78(6):345-353. PubMed ID: 38429085
[TBL] [Abstract][Full Text] [Related]
6. Short-term Endpoints for Cancer Screening Trials: Does Tumor Subtype Matter?
Owens L; Gogebakan KC; Menon U; Gulati R; Weiss NS; Etzioni R
Cancer Epidemiol Biomarkers Prev; 2023 Jun; 32(6):741-743. PubMed ID: 37259797
[TBL] [Abstract][Full Text] [Related]
7. Modelled mortality benefits of multi-cancer early detection screening in England.
Sasieni P; Smittenaar R; Hubbell E; Broggio J; Neal RD; Swanton C
Br J Cancer; 2023 Jul; 129(1):72-80. PubMed ID: 37185463
[TBL] [Abstract][Full Text] [Related]
8. Attitudes to multi-cancer early detection (MCED) blood tests for population-based screening: A qualitative study in Great Britain.
Schmeising-Barnes N; Waller J; Marlow LAV
Soc Sci Med; 2024 Apr; 347():116762. PubMed ID: 38520825
[TBL] [Abstract][Full Text] [Related]
9. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK.
Hackshaw A; Cohen SS; Reichert H; Kansal AR; Chung KC; Ofman JJ
Br J Cancer; 2021 Nov; 125(10):1432-1442. PubMed ID: 34426664
[TBL] [Abstract][Full Text] [Related]
10. Multicancer Early Detection Technologies: A Review Informed by Past Cancer Screening Studies.
Raoof S; Lee RJ; Jajoo K; Mancias JD; Rebbeck TR; Skates SJ
Cancer Epidemiol Biomarkers Prev; 2022 Jun; 31(6):1139-1145. PubMed ID: 35320352
[TBL] [Abstract][Full Text] [Related]
11. Multi-Cancer Early Detection Tests: Current Progress and Future Perspectives.
Loomans-Kropp HA; Umar A; Minasian LM; Pinsky PF
Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):512-514. PubMed ID: 35253043
[TBL] [Abstract][Full Text] [Related]
12. Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy.
Trosman JR; Weldon CB; Kurian AW; Pasquinelli MM; Kircher SM; Martin N; Douglas MP; Phillips KA
Health Aff Sch; 2023 Jul; 1(1):qxad005. PubMed ID: 38756840
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the impact of multicancer early detection testing on health and economic outcomes: Toward a decision modeling strategy.
Lipscomb J; Horton S; Kuo A; Tomasetti C
Cancer; 2022 Feb; 128 Suppl 4():892-908. PubMed ID: 35133662
[TBL] [Abstract][Full Text] [Related]
14. Patient Preferences for Multi-Cancer Early Detection (MCED) Screening Tests.
Gelhorn H; Ross MM; Kansal AR; Fung ET; Seiden MV; Krucien N; Chung KC
Patient; 2023 Jan; 16(1):43-56. PubMed ID: 35844011
[TBL] [Abstract][Full Text] [Related]
15. Testing Whether Cancer Screening Saves Lives: Implications for Randomized Clinical Trials of Multicancer Screening.
Welch HG; Dey T
JAMA Intern Med; 2023 Nov; 183(11):1255-1258. PubMed ID: 37639251
[TBL] [Abstract][Full Text] [Related]
16. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.
Klein EA; Richards D; Cohn A; Tummala M; Lapham R; Cosgrove D; Chung G; Clement J; Gao J; Hunkapiller N; Jamshidi A; Kurtzman KN; Seiden MV; Swanton C; Liu MC
Ann Oncol; 2021 Sep; 32(9):1167-1177. PubMed ID: 34176681
[TBL] [Abstract][Full Text] [Related]
17. Study design considerations for trials to evaluate multicancer early detection assays for clinical utility.
Minasian LM; Pinsky P; Katki HA; Dickherber T; Han PKJ; Harris L; Patriotis C; Srivastava S; Weil CJ; Prorok PC; Castle PE
J Natl Cancer Inst; 2023 Mar; 115(3):250-257. PubMed ID: 36458902
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor DNA Allele Fraction: A Candidate Biological Signal for Multicancer Early Detection Tests to Assess the Clinical Significance of Cancers.
Bredno J; Venn O; Chen X; Freese P; Ofman JJ
Am J Pathol; 2022 Oct; 192(10):1368-1378. PubMed ID: 35948080
[TBL] [Abstract][Full Text] [Related]
19. Multicancer Early Detection: Learning From the Past to Meet the Future.
Etzioni R; Gulati R; Weiss NS
J Natl Cancer Inst; 2022 Mar; 114(3):349-352. PubMed ID: 34450655
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA.
Chen X; Dong Z; Hubbell E; Kurtzman KN; Oxnard GR; Venn O; Melton C; Clarke CA; Shaknovich R; Ma T; Meixiong G; Seiden MV; Klein EA; Fung ET; Liu MC
Clin Cancer Res; 2021 Aug; 27(15):4221-4229. PubMed ID: 34088722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
